NVDA Q3 Earnings Alert: Why our AI stock picker is still holding Nvidia stockRead More

Palantir, Intel gain in premarket trading; Cal-Maine Foods slips

Published 05/10/2023, 12:14 am
© Reuters.
INTC
-
AAPL
-
FLR
-
NFLX
-
CALM
-
NVS
-
BROG
-
MRNA
-
PLTR
-

Investing.com -- Stocks in focus in premarket trade on Wednesday, October 4th. Please refresh for updates.

Shares in Cal-Maine Foods (NASDAQ:CALM) fell sharply after the egg producer reported first-quarter earnings per share of $0.02 versus analysts' estimates of $0.33. Revenues of $459.3 million missed projections of $473.37 million, primarily due to the decrease in the net average selling price for conventional eggs.

Palantir (NYSE:PLTR) shares jumped after Bloomberg News reported that the data analysis group is poised to secure a contract to overhaul the UK's National Health Service.

Apple (NASDAQ:AAPL) stock decreased after analysts at KeyBanc Capital Markets downgraded their rating of the iPhone maker, citing an expected slowdown in sales.

Netflix (NASDAQ:NFLX) shares edged only marginally higher after the Wall Street Journal reported that the streaming service will raise its prices for its ad-free subscription tier.

Brooge Holdings (NASDAQ:BROG) shares spiked after the infrastructure provider announced that it had received a takeover offer from UAE-based shipping group Gulf Navigation Holdings.

Intel (NASDAQ:INTC) stock gained after the semiconductor firm said it planned to spin off its programmable chip unit and hold an initial public offering for the division in two to three years.

Fluor (NYSE:FLR) shares rose after UBS upgraded its rating of the engineering group to buy.

U.S.-listed shares in Novartis (NYSE:NVS) edged down after the Swiss drugmaker completed a spin-off of its Sandoz generics and biosimilars division. Shares in the new business slipped on their market debut.

Moderna (NASDAQ:MRNA) shares inched up after the drugmaker said an early-stage study showed that its combination COVID-19 and influenza vaccine had generated a strong immune response when compared to individual jabs.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.